Page 17 - ITPS-6-2

INNOSC Theranostics and
Pharmacological Sciences Theranostics in neurosurgery

mediated blood-brain barrier disruption. Fluids Barriers based theranostic systems for combined imaging and cancer
CNS, 19: 103. therapy: Recent advances and challenges. ACS Biomater Sci
Eng, 8: 2281–2306.
https://doi.org/10.1186/s12987-022-00402-3
https://doi.org/10.1021/acsbiomaterials.1c01631
20. Arulpragasam AR, van ‘t Wout-Frank M, Barredo J, et al.,
2022, Low intensity focused ultrasound for non-invasive 32. Palmisciano P, Watanabe G, Conching A, et al., 2022, The
and reversible deep brain neuromodulation-a paradigm role of [ Ga]Ga-DOTA-SSTR PET radiotracers in brain
68
shift in psychiatric research. Front Psychiatry, 13: 825802. tumors: A systematic review of the literature and ongoing
https://doi.org/10.3389/fpsyt.2022.825802 clinical trials. Cancers (Basel), 14: 2925.
https://doi.org/10.3390/cancers14122925
21. Rabut C, Yoo S, Hurt RC, et al., 2020, Ultrasound
technologies for imaging and modulating neural activity. 33. Novruzov F, Aliyev JA, Jaunmuktane Z, et al., 2015, The use
Neuron, 108: 93–110. of (68)Ga DOTATATE PET/CT for diagnostic assessment
https://doi.org/10.1016/j.neuron.2020.09.003 and monitoring of (177)Lu DOTATATE therapy in pituitary
carcinoma. Clin Nucl Med, 40: 47–49.
22. Kubanek J, 2018, Neuromodulation with transcranial
focused ultrasound. Neurosurg Focus, 44: E14. https://doi.org/10.1097/rlu.0000000000000589
34. Milker-Zabel S, Zabel-du Bois A, Henze M, et al., 2006,
https://doi.org/10.3171/2017.11.focus17621
Improved target volume definition for fractionated
nd
23. Guo H, Hamilton M 2 , Offutt SJ, et al., 2018, Ultrasound stereotactic radiotherapy in patients with intracranial
produces extensive brain activation via a cochlear pathway. meningiomas by correlation of CT, MRI, and [ Ga]-
68
Neuron, 98: 1020–1030.e4. DOTATOC-PET. Int J Radiat Oncol Biol Phys, 65: 222–227.
https://doi.org/10.1016/j.neuron.2018.04.036 https://doi.org/10.1016/j.ijrobp.2005.12.006
24. Zhou YF, 2011, High intensity focused ultrasound in clinical 35. Gehler B, Paulsen F, Oksüz MO, et al., 2009, [ Ga]-
68
tumor ablation. World J Clin Oncol, 2: 8–27. DOTATOC-PET/CT for meningioma IMRT treatment
https://doi.org/10.5306/wjco.v2.i1.8 planning. Radiat Oncol, 4: 56.
25. Bunevicius A, McDannold NJ, Golby AJ, 2020, Focused https://doi.org/10.1186/1748-717X-4-56
ultrasound strategies for brain tumor therapy. Oper 36. Kowalski ES, Khairnar R, Gryaznov AA, et al., 2021,
Neurosurg (Hagerstown), 19: 9–18. 68Ga-DOTATATE PET-CT as a tool for radiation
https://doi.org/10.1093/ons/opz374 planning and evaluating treatment responses in the clinical
management of meningiomas. Radiat Oncol, 16: 151.
26. Hersh AM, Bhimreddy M, Weber-Levine C, et al., 2022,
Applications of focused ultrasound for the treatment of https://doi.org/10.1186/s13014-021-01875-6
glioblastoma: A new frontier. Cancers (Basel), 14: 4920. 37. Marincek N, Radojewski P, Dumont RA, et al., 2015,
https://doi.org/10.3390/cancers14194920 Somatostatin receptor-targeted radiopeptide therapy with
90Y-DOTATOC and 177Lu-DOTATOC in progressive
27. Maesawa S, Nakatsubo D, Tsugawa T, et al., 2021, Magnetic meningioma: Long-term results of a phase II clinical trial.
resonance-guided focused ultrasound ablation: Techniques J Nucl Med, 56: 171–176.
and neurological applications. No Shinkei Geka, 49: 847–856.
https://doi.org/10.2967/jnumed.114.147256
https://doi.org/10.11477/mf.1436204463
38. Gerster-Gilliéron K, Forrer F, Maecke H, et al., 2015,
28. Patel NA, Nycz CJ, Carvalho PA, et al., 2020, An integrated 90Y-DOTATOC as a therapeutic option for complex
robotic system for MRI-guided neuroablation: Preclinical recurrent or progressive meningiomas. J Nucl Med,
evaluation. IEEE Trans Biomed Eng, 67: 2990–2999.
56: 1748–1751.
https://doi.org/10.1109/tbme.2020.2974583
https://doi.org/10.2967/jnumed.115.155853
29. Morris ZS, Wang AZ, Knox SJ, 2021, The radiobiology of 39. Bartolomei M, Bodei L, De Cicco C, et al., 2009, Peptide
radiopharmaceuticals. Semin Radiat Oncol, 31: 20–27. receptor radionuclide therapy with (90)Y-DOTATOC
https://doi.org/10.1016/j.semradonc.2020.07.002 in recurrent meningioma. Eur J Nucl Med Mol Imaging,
36: 1407–1416.
30. Sgouros G, Bodei L, McDevitt MR, et al., 2020,
Radiopharmaceutical therapy in cancer: Clinical advances https://doi.org/10.1007/s00259-009-1115-z
and challenges. Nat Rev Drug Discov, 19: 589–608.
40. Otte A, Herrmann R, Heppeler A, et al., 1999, Yttrium-90
https://doi.org/10.1038/s41573-020-0073-9 DOTATOC: First clinical results. Eur J Nucl Med, 26: 1439–1447.
31. Gupta A, Sood A, Fuhrer E, et al., 2022, Polysaccharide- https://doi.org/10.1007/s002590050476

Volume 6 Issue 2 (2023) 11 https://doi.org/10.36922/itps.417